The Prevalence and Significance of Leukopenia Induced by Intravenous Iron Therapy in a Large Cohort of Females with Iron Deficiency Anemia (IDA) Leukopenia Induced by Intravenous Iron Therapy in Females with Iron Deficiency Anemia
Main Article Content
: Intravenous iron therapy, neutrophils, lymphocytes, iron deficiency anemia, infections.
Introduction: Iron deficiency anemia (IDA) is the most common cause of anemia in both developed and developing countries. Leukopenia is an infrequent side effect of iron therapy reported in the literature as sporadic cases. Objective: To assess the prevalence of leukopenia, neutropenia and/or lymphocytopenia and its possible clinical impact if any, after intravenous iron therapy in adult patients with IDA. Patients and Methods: This is a retrospective study conducted in Hamad Medical Corporation, Doha (Qatar). The clinical and biochemical data of 1.567 females (mean age: 29.5 years) with IDA who attended the Hematology Clinic and were treated with intravenous (i.v.) iron therapy were collected and analysed. Complete and differential blood counts and iron profile were studied before and after i.v. iron therapy. In addition, cases who developed infections during the time of leukopenia were noted and checked for possible complications. Results: 30 cases (1.91%) developed leukopenia,15 cases (0.95%) developed neutropenia and 12 cases (0.76%) developed lymphocytopenia. All had normal white blood cell counts before treatment. Two patients (6.66%) had infection. One had upper respiratory tract infection and the other had urinary tract infection, the latter was treated with antibiotics. There was no reported other infection during or after i.v. iron therapy. Conclusions: Leukopenia in form of neutropenia or lymphocytopenia may occur as a side effect of i.v. iron therapy, however, its clinical significance appears to be limited.
2. Rector WG. Pica: its frequency and significance in patients with iron-deficiency anemia due to chronic gastrointestinal blood loss. J Gen Intern Med. 1989;4:512–3.
3. Haas JD, Fairchild MW. Summary and conclusions of the International Conference on Iron Deficiency and Behavioral Development, October 10–12, 1988. Am J Clin Nutr. 1989;50:703–5.
4. Rasmussen K. Is There a Causal Relationship between Iron Deficiency or Iron-Deficiency Anemia and Weight at Birth, Length of Gestation and Perinatal Mortality? J Nutr. 2001;131(2S-2):590S-601S; discussion 601S-603S.
5. Dunne JR, Malone D, Tracy JK, Gannon C, Napolitano LM. Perioperative anemia: an independent risk factor for infection, mortality, and resource utilization in surgery. J Surg Res. 2002;102:237–44.
6. Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoiesis. Transfusion, 2012;52:1584-92.
7. KDOQI, National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis2006;47(5 suppl 3):S16-85.
8. Tvedten H, Raskin RE. Leukocyte Disorders. Small Animal Clinical Diagnosis by Laboratory Methods. 2012;63-91. doi:10.1016/B978-1-4377-0657-4.00004-1.
9. Litton E, Xiao J, Ho KM. Safety, and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013;347:f4822.
10. Lima CSP, Paula EV, Takahashi T, Saad STO, Lorand-Metze I, Costa FF. Causes of incidental neutropenia in adulthood. Ann Hematol. 2006;85:705–9.
11. Castelino DJ, McNair P, Kay TW. Lymphocytopenia in a hospital population--what does it signify? Aust N Z J Med. 1997;27:170–4.
12. Tavakolpour S, Rakhshandehroo T, Wei EX, Rashidian M. Lymphopenia during the COVID-19 infection: What it shows and what can be learned. Immunol Lett. 2020;225:31–2.
13. Almasri HA, Soliman AT, De Sanctis V, Al-Tikrity MA, Alsaud AE, Ahmad RW, et al. The Prevalence and Clinical Impact of Leukopenia Among Arab Population with Iron Deficiency Anemia an Experience from Qatar. Blood. 2020;136(Supplement 1):16.
14. Almasri HA, Soliman AT, De Sanctis V, Alsaud AE, Babikir MM, Kloub MN, et al. The Prevalence and Clinical Impact of Neutropenia Among Arab Population with Iron Deficiency Anemia an Experience from Qatar. Blood. 2020;136(Supplement 1):19–20.
15. Almasri HA, Soliman AT, De Sanctis V, Ahmad RW, Al-Tikrity MA, Alhashimy R, et al. The Prevalence of Lymphocytopenia Among Arab Population with Iron Deficiency Anemia an Experience from Qatar. Blood. 2020;136(Supplement 1):15–6.
16. Babikir M, Ahmad R, Soliman A, Al-Tikrity M, Yassin MA. Iron-Induced Thrombocytopenia: A Mini-Review of the Literature and Suggested Mechanisms. Cureus [Internet]. 2020;12(9): e10201.
17. Brito-Babapulle FM. Bone Marrow suppression Due to ferric Carboxymaltose Infusion. First Reported Case. Blood. 2013;122:4673–73.
18. Kloub MN, Yassin MA. Oral Iron Therapy-Induced Neutropenia in Patient with Iron Deficiency Anemia. Case Rep Oncol. 2020;13:721–4.
19. Renassia C, Louis S, Cuvellier S, Boussetta N, Deschemin J-C, Borderie D, et al. Neutrophils from hereditary hemochromatosis patients are protected from iron excess and are primed. Blood Adv. 2020;4:3853–63.
16. Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol CJASN. 2006;1 (Suppl 1):S19-23.
17. Tanaka H, Espinoza JL, Fujiwara R, Rai S, Morita Y, Ashida T, et al. Excessive Reactive Iron Impairs Hematopoiesis by Affecting Both Immature Hematopoietic Cells and Stromal Cells. Cells. 2019;8:226.
18. Fishbane S. Review of issues relating to iron and infection. Am J Kidney Dis.1999 ;34(4 Suppl 2):S47-52.
19. Fell LH, Zawada AM, Rogacev KS, Seiler S, Fliser D, Heine GH. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2014;29:809–22.
20. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015 ;90:12–23.
20. Kalra PA, Bhandari S. Safety of intravenous iron use in chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25:529–35.
21. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015;88:905–14.
22. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–48.